HIV/AIDS News CME/CE

• FDA Safety Changes: DepoDur, Neoral, Lexiva CME/CE The FDA has approved safety labeling revisions for morphine sulfate extended-release liposome injection, cyclosporine capsules and oral solution, and fosamprenavir calcium tablets and oral suspension.
  Medscape Medical News CME, November 2009
• FDA Safety Changes: Ultram, Ultracet, Sustiva, Kayexalate CME/CE The FDA has approved safety labeling revisions for tramadol HCl tablets, tramadol plus acetaminophen tablets, efavirenz capsules and tablets, and sodium polystyrene sulfonate powder.
  Medscape Medical News CME, October 2009
• FDA Approvals: Zirgan, Prism HIV, Valturna CME/CE The FDA has approved ganciclovir ophthalmic gel to treat herpetic keratitis, a screening test for HIV types 1 and 2, and a single-pill combination of aliskiren and valsartan to treat hypertension.
  Medscape Medical News CME, October 2009
• Guidelines Issued for Management of Opportunistic Infections Among HIV-Exposed Children CME/CE The CDC and other organizations have updated previous guidelines for children who have been exposed to HIV or who are infected with HIV, and who are therefore at increased risk for OIs.
  Medscape Medical News CME, September 2009
• Primary Care Guidelines Updated for Management of HIV CME/CE The HIV Medicine Association of the Infectious Diseases Society of America has issued updated, evidence-based guidelines for management of HIV.
  Medscape Medical News CME, August 2009
• Hepatitis C Virus Coinfection Ups Risk of HIV-Related Infections CME HIV-infected patients coinfected with hepatitis C virus are more than 3 times likely to have an HIV-related bacterial or mycotic infection vs patients without hepatitis C virus coinfection.
  Reuters Health Information CME, August 2009
• Raltegravir May Be a Well-Tolerated Alternative to Efavirenz for HIV-1 Combination Therapy CME A study shows that raltegravir-based combination therapy in treatment-naive patients with HIV-1 infection has rapid, potent antiretroviral activity noninferior to that of efavirenz at week 48.
  Medscape Medical News CME, August 2009
• FDA Safety Changes: Strattera, Aptivus, CellCept CME/CE The FDA has approved safety labeling revisions for atomoxetine HCl capsules; tipranavir capsules and oral solution; and mycophenolate mofetil capsules, tablets, injection, and oral suspension.
  Medscape Medical News CME, August 2009
• HIV Susceptibility Testing May Improve Survival Among HAART-Experienced Patients CME In a cohort study, use of genotypic and phenotypic susceptibility testing was independently associated with improved survival among HAART-experienced patients.
  Medscape Medical News CME, July 2009
• FDA Safety Changes: Aristospan, Videx/Videx EC, Coreg/Coreg ER CME/CE The FDA has approved safety labeling revisions for triamcinolone hexacetonide, didanosine oral solution and delayed-release capsules, carvedilol tablets, and carvedilol extended-release tablets.
  Medscape Medical News CME, July 2009
• CVD Risks of HIV Infection Underestimated CME HIV infection per se is an independent risk factor for preclinical atherosclerosis, with the magnitude of the effect being similar to that of known risk factors, such as smoking and diabetes.
  Heartwire CME, July 2009
• Early vs Deferred Antiretroviral Therapy May Reduce AIDS Progression and Death CME In a randomized trial, early vs late antiretroviral therapy was associated with approximately half the rate of AIDS progression and death, with no increase in adverse events or loss of virologic response.
  Medscape Medical News, May 2009
• FDA Safety Changes: Epzicom, Trizivir, Tracleer CME/CE The FDA has approved safety labeling revisions for abacavir sulfate and lamivudine tablets (Epzicom), abacavir plus lamivudine and zidovudine tablets (Trizivir), and bosentan tablets (Tracleer).
  Medscape Medical News, April 2009
• A Single Dose of Nevirapine May Establish Antiretroviral Resistance Within the Latent Reservoir CME/CE This finding suggests a potentially lifelong risk for reemergence of nevirapine-resistant HIV and mandates strategies to prevent transmission that do not compromise successful future treatment.
  Medscape Medical News, April 2009
• FDA Safety Changes: Tracleer, Nexium, Nexium IV, Tygacil CME/CE The FDA has approved revisions to the safety labeling for bosentan tablets, esomeprazole injection, esomeprazole magnesium delayed-release capsules and oral suspension, and tigecycline injection.
  Medscape Medical News, April 2009
• Guidelines Updated for Management of Opportunistic Infections in HIV-Infected Adults and Teens CME The Centers for Disease Control, National Institutes of Health, and others have updated guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.
  Medscape Medical News, March 2009
• FDA Safety Changes: Celebrex, Crixivan, Rifater CME/CE The FDA has approved revisions to the safety labeling for celecoxib capsules (Celebrex), indinavir sulfate tablets (Crixivan), and isoniazid plus pyrazinamide and rifampin tablets (Rifater).
  Medscape Medical News, March 2009
• Alert FDA Safety Changes: Selzentry, Triglide, Neulasta CME The FDA has approved revisions to the safety labeling for maraviroc tablets, fenofibrate tablets, and pegfilgrastim.
  Medscape Medical News, February 2009
• FDA Safety Changes: Prevacid NapraPAC 500, Prezista, Arixtra CME The FDA has approved revisions to the safety labeling for lansoprazole delayed-release capsules and naproxen tablet kit, darunavir tablets, and fondaparinux sodium injection.
  Medscape Medical News, January 2009
• FDA Safety Changes: Atrovent and Atripla CME The FDA has approved revisions to the safety labeling for ipratropium Br nasal spray (Atrovent) and for efavirenz/emtricitabine/tenofovir disoproxil fumarate tablets (Atripla).
  Medscape Medical News, January 2009